Profund Advisors LLC Trims Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Profund Advisors LLC lowered its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 48.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 27,421 shares of the company’s stock after selling 26,026 shares during the quarter. Profund Advisors LLC’s holdings in Dyne Therapeutics were worth $968,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Concurrent Investment Advisors LLC bought a new position in Dyne Therapeutics in the 1st quarter worth about $573,000. Sei Investments Co. purchased a new stake in Dyne Therapeutics in the first quarter valued at approximately $693,000. Rafferty Asset Management LLC lifted its position in Dyne Therapeutics by 17.7% during the fourth quarter. Rafferty Asset Management LLC now owns 164,041 shares of the company’s stock valued at $2,182,000 after purchasing an additional 24,632 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new position in Dyne Therapeutics in the 1st quarter worth approximately $810,000. Finally, Commodore Capital LP purchased a new position in Dyne Therapeutics in the 4th quarter worth approximately $11,970,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on DYN shares. Morgan Stanley lifted their price objective on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Stifel Nicolaus raised their price objective on Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a report on Friday, August 16th. JPMorgan Chase & Co. upped their target price on Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 9th. Finally, Guggenheim increased their price target on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. One analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $51.40.

Dyne Therapeutics Stock Down 5.4 %

Shares of Dyne Therapeutics stock opened at $34.63 on Tuesday. The company’s fifty day simple moving average is $40.89 and its two-hundred day simple moving average is $33.71. Dyne Therapeutics, Inc. has a 12-month low of $6.40 and a 12-month high of $47.45. The firm has a market cap of $3.03 billion, a PE ratio of -8.72 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.02. As a group, sell-side analysts expect that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO John Cox acquired 32,000 shares of Dyne Therapeutics stock in a transaction on Wednesday, September 4th. The shares were acquired at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the transaction, the chief executive officer now owns 8,000 shares in the company, valued at $264,320. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, SVP Richard William Scalzo sold 1,390 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total value of $48,024.50. Following the completion of the transaction, the senior vice president now owns 98,568 shares in the company, valued at approximately $3,405,524.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO John Cox purchased 32,000 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, September 4th. The stock was purchased at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the completion of the purchase, the chief executive officer now owns 8,000 shares of the company’s stock, valued at $264,320. The disclosure for this purchase can be found here. Insiders sold 12,705 shares of company stock valued at $437,701 over the last quarter. 20.77% of the stock is owned by company insiders.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.